ECSP18012103A - Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) - Google Patents

Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)

Info

Publication number
ECSP18012103A
ECSP18012103A ECIEPI201812103A ECPI201812103A ECSP18012103A EC SP18012103 A ECSP18012103 A EC SP18012103A EC IEPI201812103 A ECIEPI201812103 A EC IEPI201812103A EC PI201812103 A ECPI201812103 A EC PI201812103A EC SP18012103 A ECSP18012103 A EC SP18012103A
Authority
EC
Ecuador
Prior art keywords
csf
inhibitors
stimulating factor
factor receptor
colony stimulating
Prior art date
Application number
ECIEPI201812103A
Other languages
English (en)
Inventor
Andrew Scholte
Jinyu Liu
Tieu-Binh Le
John L Kane Jr
Barret Giese
Patrick Shum
Markus Metz
Paul Erdman
Liang Ma
Limli Wei
Vinod Patel
Mark Czekaj
Claude Barberis
Michael Kothe
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of ECSP18012103A publication Critical patent/ECSP18012103A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Compuestos de fórmulas I y II, que son útiles como inhibidores del receptor del factor estimulador de colonias 1 (CSF-1R) (“inhibidores de CSF
ECIEPI201812103A 2015-07-20 2018-02-19 Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r) ECSP18012103A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562194619P 2015-07-20 2015-07-20

Publications (1)

Publication Number Publication Date
ECSP18012103A true ECSP18012103A (es) 2018-04-30

Family

ID=56551024

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201812103A ECSP18012103A (es) 2015-07-20 2018-02-19 Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)

Country Status (27)

Country Link
US (3) US11274108B2 (es)
EP (1) EP3325471A1 (es)
JP (4) JP6898914B2 (es)
KR (1) KR102665765B1 (es)
CN (1) CN107922396B (es)
AR (1) AR105392A1 (es)
AU (3) AU2016297558B2 (es)
BR (1) BR112018001017B1 (es)
CA (2) CA2993018C (es)
CL (1) CL2018000140A1 (es)
CO (1) CO2018001621A2 (es)
CR (1) CR20180109A (es)
DO (1) DOP2018000008A (es)
EC (1) ECSP18012103A (es)
GT (1) GT201800020A (es)
IL (3) IL305843B2 (es)
MA (1) MA42023B2 (es)
MX (2) MX388540B (es)
MY (1) MY186368A (es)
PE (1) PE20180573A1 (es)
PH (1) PH12018500140A1 (es)
RU (1) RU2748884C2 (es)
SG (1) SG10201912699RA (es)
TN (1) TN2018000020A1 (es)
TW (1) TWI734693B (es)
WO (1) WO2017015267A1 (es)
ZA (1) ZA201800082B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2831582C (en) 2011-03-28 2019-01-08 Mei Pharma, Inc. (alpha-substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
SG10201912699RA (en) 2015-07-20 2020-02-27 Genzyme Corp Colony stimulating factor-1 receptor (csf-1r) inhibitors
CA3063976A1 (en) 2017-05-23 2018-11-29 Mei Pharma, Inc. Combination therapy
RU2020105929A (ru) 2017-08-04 2021-09-06 Скайхоук Терапьютикс, Инк. Способы и композиции для модулирования сплайсинга
MX2020001727A (es) 2017-08-14 2020-03-20 Mei Pharma Inc Terapia de combinacion.
EP3920926A4 (en) 2019-02-05 2022-10-19 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
JP7603592B2 (ja) 2019-02-05 2024-12-20 スカイホーク・セラピューティクス・インコーポレーテッド スプライシングを調節するための方法および組成物
CN119638696A (zh) 2019-02-06 2025-03-18 斯基霍克疗法公司 用于调节剪接的方法和组合物
WO2020163544A1 (en) 2019-02-06 2020-08-13 Skyhawk Therapeutics, Inc. Methods and compositions for modulating splicing
EP3950063A4 (en) * 2019-03-29 2022-11-30 Kowa Company, Ltd. NOVEL AZAINDO DERIVATIVE
AU2021313150A1 (en) 2020-07-20 2023-03-16 Nido Biosciences, Inc. Indole compounds as androgen receptor modulators
CA3195511A1 (en) * 2020-09-21 2022-03-24 Hutchison Medipharma Limited Heteroaromatic compounds and uses thereof
BR112023005445A2 (pt) * 2020-09-25 2023-05-09 Jumbo Drug Bank Co Ltd Compostos de 1h-pirrolo[2,3-c]piridina e aplicação dos mesmos
EP4267573A1 (en) * 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
CN116848110A (zh) * 2020-12-23 2023-10-03 建新公司 氘代集落刺激因子-1受体（csf-1r）抑制剂
WO2022140528A1 (en) 2020-12-23 2022-06-30 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
AU2023238511B2 (en) * 2022-03-25 2025-11-27 Jumbo Drug Bank Co., Ltd. Crystal form of 1h-pyrrolo[2,3-c]pyridine compound and preparation method therefor
AU2023289905A1 (en) 2022-06-22 2025-02-06 Genzyme Corporation Solid forms of deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
CN118206507A (zh) * 2023-03-22 2024-06-18 中国医学科学院医药生物技术研究所 一种含硒化合物及其制备方法与用途
TW202535870A (zh) * 2023-10-26 2025-09-16 日商大塚製藥股份有限公司 作為csf1r抑制劑之化合物

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612323A (en) * 1983-06-27 1986-09-16 Sumitomo Chemical Company, Limited Insecticidal and acaricidal derivatives of 1-benzylbenzimidazole
JPS61118380A (ja) * 1984-11-14 1986-06-05 Shionogi & Co Ltd 新規な１，４−ベンゾジオキサンおよび１，４−ベンゾジオキシン誘導体ならびにその製造法
JPS61151176A (ja) * 1984-12-24 1986-07-09 Sumitomo Chem Co Ltd ベンズイミダゾール誘導体およびそれを有効成分とする殺虫、殺ダニ剤
JPH07116183B2 (ja) * 1987-03-31 1995-12-13 三菱化学株式会社 チアジアゾ−ル誘導体及びこれを有効成分とする殺虫殺ダニ剤
ES2051939T3 (es) 1988-08-05 1994-07-01 Basf Ag Heteroaromatos fenoxialquilsubstituidos, procedimientos para su obtencion y su empleo para la lucha contra las pestes.
ZA913760B (en) * 1990-05-24 1992-02-26 Sumitomo Chemical Co Pyridine derivatives,their production processes and their compounds for control of insect pests
DE4227791A1 (de) 1991-08-24 1993-02-25 Schering Ag Pyrrolo (2,3c)-pyridinderivate, deren herstellung und verwendung in arzneimitteln
US5187159A (en) * 1991-10-07 1993-02-16 Merck & Co., Inc. Angiotensin II antagonists incorporating a substituted 1,3-benzodioxole or 1,3-benzodithiole
US5478832A (en) 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
AU4348593A (en) * 1992-06-25 1994-01-24 Zeneca Limited Chromanderivatives as angiotensin ii antagonists
FR2693197B1 (fr) * 1992-07-03 1994-09-23 Synthelabo Nouveaux dérivés de quinoléine, leur procédé de préparation et leur application thérapeutique.
US6765008B1 (en) * 1992-12-17 2004-07-20 Pfizer Inc Pyrrolopyrimidines as CRF antagonists
ZA939516B (en) 1992-12-22 1994-06-06 Smithkline Beecham Corp Endothelin receptor antagonists
JPH07138259A (ja) 1993-06-30 1995-05-30 Asahi Glass Co Ltd イミダゾール誘導体の製造法
JPH09202774A (ja) * 1996-01-25 1997-08-05 Green Cross Corp:The ２−アリールキノリン類およびその製造方法
JPH101471A (ja) 1996-06-13 1998-01-06 Green Cross Corp:The Ｎ−［（キノリン−２−イル）フェニル］スルホンアミド類の結晶およびその製造方法
CN1235546A (zh) * 1996-08-30 1999-11-17 吉富制药株式会社 肌肉组织变性的预防或治疗剂
CA2293418A1 (en) 1997-06-19 1998-12-23 Michael Z. Hoemann Quinoline-indole antimicrobial agents, uses and compositions related thereto
WO1999000372A1 (fr) 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Sulfamides et leur utilisation medicale
CN1268137A (zh) 1997-07-03 2000-09-27 杜邦药品公司 治疗神经失调的咪唑并嘧啶和咪唑并吡啶
DE19845153A1 (de) 1998-10-01 2000-04-06 Merck Patent Gmbh Imidazo[4,5]-pyridin-4-on-derivate
US6130333A (en) * 1998-11-27 2000-10-10 Monsanto Company Bicyclic imidazolyl derivatives as phosphodiesterase inhibitors, pharmaceutical compositions and method of use
JP2001039874A (ja) 1999-07-28 2001-02-13 Welfide Corp 肺高血圧症予防治療剤
MXPA02008801A (es) 2000-03-09 2003-07-07 Ono Pharmaceutical Co Derivados de indol, proceso para la preparacion de los mismos y su uso.
US7135495B2 (en) * 2000-03-09 2006-11-14 Ono Pharmaceutical Co., Ltd. Indole derivatives
PA8535601A1 (es) 2000-12-21 2002-11-28 Pfizer Derivados benzimidazol y piridilimidazol como ligandos para gabaa
US7030150B2 (en) * 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
DE60318198T2 (de) * 2002-05-02 2008-12-04 Merck & Co., Inc. Tyrosinkinase-hemmer
BRPI0406883A (pt) 2003-01-22 2006-01-03 Lilly Co Eli Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
US7531553B2 (en) 2003-03-21 2009-05-12 Amgen Inc. Heterocyclic compounds and methods of use
EP1613311A4 (en) 2003-03-27 2010-04-14 Univ Emory HIF-1 INHIBITORS
DE10342503A1 (de) * 2003-09-12 2005-04-14 Merck Patent Gmbh Benzyl-Benzimidazolylderivate
EP2145888A1 (en) * 2003-09-18 2010-01-20 Conforma Therapeutics Corporation Deazapurine derivatives as HSP90-Inhibitors
JP2007520559A (ja) 2004-02-03 2007-07-26 アボット・ラボラトリーズ 治療薬としてのアミノベンゾオキサゾール類
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
CA2570817A1 (en) 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
DE602005020957D1 (de) 2004-09-03 2010-06-10 Yuhan Corp Pyrroloä3,2-cüpyridinderivate und verfahren zu deren herstellung
TWI278682B (en) 2004-11-23 2007-04-11 Ind Tech Res Inst Fiber optic interferometric position sensor and measuring method thereof
KR20070086865A (ko) 2004-12-01 2007-08-27 오에스아이 파마슈티컬스, 인코포레이티드 Ｎ-치환된 벤즈이미다졸일 ｃ-ｋｉｔ 억제제 및 조합적인벤즈이미다졸 라이브러리
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
MX2007014377A (es) 2005-05-17 2008-02-06 Plexxikon Inc Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina.
PL2395004T3 (pl) 2005-06-22 2016-08-31 Plexxikon Inc Pochodne pirolo[2,3-b]pirydyny jako inhibitory kinazy białkowej
CN102127078A (zh) * 2005-07-14 2011-07-20 安斯泰来制药株式会社 Janus激酶3的杂环类抑制剂
US7402684B2 (en) 2005-09-21 2008-07-22 Decode Genectics Ehf. Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation
NL2000613C2 (nl) * 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
SI2084162T1 (sl) 2006-10-23 2012-11-30 Sgx Pharmaceuticals Inc Biciklični triazoli kot modulatroji proteinskih kinaz
PL2081937T3 (pl) 2006-10-23 2013-01-31 Sgx Pharmaceuticals Inc Triazolopirydazynowe modulatory kinaz białkowych
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
WO2008064199A1 (en) * 2006-11-22 2008-05-29 Johnson Controls Technology Company Multichannel evaporator with flow separating manifold
US7872018B2 (en) 2006-12-21 2011-01-18 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
JP2010524953A (ja) * 2007-04-17 2010-07-22 ブリストル−マイヤーズ スクイブ カンパニー 縮合ヘテロ環１１−β−ヒドロキシステロイドデヒドロゲナーゼＩ型阻害剤
EP2178563A2 (en) 2007-07-06 2010-04-28 OSI Pharmaceuticals, Inc. Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mtorc2
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
AU2008323694A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
WO2009139834A1 (en) 2008-05-13 2009-11-19 Poniard Pharmaceuticals, Inc. Bioactive compounds for treatment of cancer and neurodegenerative diseases
US8158636B2 (en) * 2008-05-19 2012-04-17 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
CA2733554A1 (en) 2008-08-18 2010-02-25 Yale University Mif modulators
WO2010078307A1 (en) 2008-12-29 2010-07-08 Xenon Pharmaceuticals Inc. Spiro-oxindole-derivatives as sodium channel blockers
CA2759547A1 (en) 2009-04-22 2010-10-28 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
ES2715611T3 (es) * 2010-05-17 2019-06-05 Incozen Therapeutics Pvt Ltd Compuestos novedosos de 3H-imidazo[4,5-b]piridina-3,5-disustituida y 3H-[1,2,3]triazolo[4,5-b]piridina 3,5-disustituida como moduladores de proteína cinasas
WO2011156632A2 (en) * 2010-06-09 2011-12-15 Georgetown University Compositions and methods of treatment for tumors in the nervous system
US8835472B2 (en) 2010-09-02 2014-09-16 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
AU2011332196A1 (en) 2010-11-24 2013-07-11 Allergan, Inc. Indole derivatives as modulators of S1P receptors
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
US8748435B2 (en) 2011-04-01 2014-06-10 Novartis Ag Pyrazolo pyrimidine derivatives
WO2012160464A1 (en) 2011-05-26 2012-11-29 Daiichi Sankyo Company, Limited Heterocyclic compounds as protein kinase inhibitors
US8609653B2 (en) 2011-07-15 2013-12-17 Glaxosmithkline Llc Azaindole compounds and methods for treating HIV
CN104024257A (zh) 2011-10-04 2014-09-03 吉利德卡利斯托加有限责任公司 Pi3k的新的喹喔啉抑制剂
CA2851155C (en) * 2011-10-14 2021-02-23 Ambit Biosciences Corporation Heterocyclic compounds and methods of use thereof
AU2012332895B2 (en) * 2011-11-03 2015-12-17 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
WO2013116182A1 (en) * 2012-01-31 2013-08-08 Boehringer Ingelheim International Gmbh Heterocyclic compounds as inhibitors of leukotriene production
MX359989B (es) * 2012-02-17 2018-10-18 Siga Tech Inc Fármacos antivirales para el tratamiento de la infección por arenavirus.
US9358235B2 (en) 2012-03-19 2016-06-07 Plexxikon Inc. Kinase modulation, and indications therefor
CN107082779A (zh) * 2012-03-30 2017-08-22 理森制药股份公司 作为c‑met 蛋白激酶调节剂的新化合物
AU2013276520A1 (en) 2012-06-15 2014-12-04 Janssen Sciences Ireland Uc 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents
US9566310B2 (en) 2012-09-10 2017-02-14 Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno Methods of treating muscular dystrophy
AU2013348018A1 (en) * 2012-11-20 2015-06-04 Discoverybiomed, Inc. Small molecule CFTR correctors
CN105968115B (zh) 2013-04-17 2018-11-09 上海医药集团股份有限公司 喹啉类化合物、其制备方法、中间体、药物组合物和应用
TWI663159B (zh) * 2013-12-10 2019-06-21 美商健臻公司 原肌球蛋白相關之激酶（ｔｒｋ）抑制劑
EP3089980B1 (en) * 2013-12-30 2018-01-31 Array Biopharma, Inc. Serine/threonine kinase inhibitors
CN105001213B (zh) 2014-04-14 2020-08-28 上海迪诺医药科技有限公司 C-芳基糖苷衍生物、其药物组合物、制备方法及应用
WO2015168269A1 (en) 2014-05-01 2015-11-05 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
TWI780438B (zh) 2014-12-18 2022-10-11 美商健臻公司 原肌球蛋白相關激酶（ｔｒｋ）抑制劑之醫藥調配物
US10272074B2 (en) * 2015-01-29 2019-04-30 Sanford Burnham Prebys Medical Discovery Institute Inhibitors of glucocorticoid receptor translocation
SG10201912699RA (en) 2015-07-20 2020-02-27 Genzyme Corp Colony stimulating factor-1 receptor (csf-1r) inhibitors
CN110526916B (zh) 2018-05-23 2021-07-13 海创药业股份有限公司 氘代Capmatinib化合物及其用途
EP4267573A1 (en) 2020-12-23 2023-11-01 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors

Also Published As

Publication number Publication date
SG10201912699RA (en) 2020-02-27
JP6898914B2 (ja) 2021-07-07
PE20180573A1 (es) 2018-04-04
CO2018001621A2 (es) 2018-02-28
IL276292A (en) 2020-09-30
IL256964B (en) 2021-10-31
WO2017015267A1 (en) 2017-01-26
BR112018001017B1 (pt) 2024-02-15
IL256964A (en) 2018-03-29
JP7652867B2 (ja) 2025-03-27
CR20180109A (es) 2018-05-03
CA3217238A1 (en) 2017-01-26
AU2021204116B2 (en) 2022-12-01
US20220396588A1 (en) 2022-12-15
JP2021107414A (ja) 2021-07-29
CA2993018A1 (en) 2017-01-26
AU2021204116A1 (en) 2021-07-15
AU2016297558B2 (en) 2021-03-25
AR105392A1 (es) 2017-09-27
TWI734693B (zh) 2021-08-01
AU2023201013A1 (en) 2023-03-23
ZA201800082B (en) 2018-12-19
EP3325471A1 (en) 2018-05-30
CA2993018C (en) 2026-02-10
MX2018000880A (es) 2018-08-24
NZ739951A (en) 2024-02-23
RU2018106060A3 (es) 2019-12-13
IL305843B2 (en) 2025-01-01
BR112018001017A2 (pt) 2018-09-18
JP2025094019A (ja) 2025-06-24
DOP2018000008A (es) 2018-05-15
US20240217991A1 (en) 2024-07-04
MX2021015102A (es) 2022-02-21
TN2018000020A1 (en) 2019-07-08
AU2023201013B2 (en) 2025-02-06
IL305843B1 (en) 2024-09-01
JP7401482B2 (ja) 2023-12-19
MX388540B (es) 2025-03-20
CL2018000140A1 (es) 2018-08-17
AU2016297558A1 (en) 2018-03-08
RU2748884C2 (ru) 2021-06-01
JP2024028845A (ja) 2024-03-05
KR20180030199A (ko) 2018-03-21
US12503477B2 (en) 2025-12-23
JP2018524381A (ja) 2018-08-30
IL276292B2 (en) 2024-02-01
GT201800020A (es) 2019-10-21
PH12018500140A1 (en) 2018-07-23
CN107922396B (zh) 2022-08-05
MA42023B2 (fr) 2022-01-31
IL305843A (en) 2023-11-01
MY186368A (en) 2021-07-16
US20190016707A1 (en) 2019-01-17
KR102665765B1 (ko) 2024-05-10
TW201716393A (zh) 2017-05-16
IL276292B1 (en) 2023-10-01
RU2018106060A (ru) 2019-08-20
US11274108B2 (en) 2022-03-15
CN107922396A (zh) 2018-04-17

Similar Documents

Publication Publication Date Title
ECSP18012103A (es) Inhibidores del receptor del factor estimulador de colonias 1 (csf-1r)
JOP20190194B1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
MX390347B (es) Compuestos de aminotiazol como inhibidores de c-kit.
CL2017002483A1 (es) Compuestos heterocíclicos como inhibidores de lsd1
UY36311A (es) Indazoles sustituidos con bencilo
EA201891211A1 (ru) Ингибиторы cxcr2
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
MX2017008444A (es) Picolinamidas como fungicidas.
MX2017008060A (es) Picolinamidas con actividad fungicida.
CR20160321A (es) Modulares de tetrahidropiridopirazinas de gpr6
MX375352B (es) Reguladores de nrf2.
AR101905A1 (es) Compuestos bicíclicos
MX2016015062A (es) Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina los cuales son inhibidores de janus cinasas (jak).
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
EA201890572A1 (ru) Биофармацевтические композиции
UY36070A (es) Triterpenoides con actividad inhibidora de la maduración de hiv
CL2016001623A1 (es) Compuestos de benzamida y nicotinamida y métodos para usar los mismos.
UA117779C2 (uk) Піразини як модулятори gpr6
MX2021008225A (es) Composiciones y metodos para tratamiento de crecimiento celular anormal.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
CL2018000941A1 (es) Regulación del uso de nitrógeno
PY1508111A (es) Polimorfos